



2026 – Outlook Webinar

Gary Phillips, CEO

3 February 2026

FORWARD LOOKING STATEMENT

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

2026 – Outlook Webinar

Participants



Hashan De Silva Non Executive Director

- Experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors.
- Worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research.
- Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.



Gary Phillips CEO

- More than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia
- Joined Pharmaxis in 2003 and was appointed Chief Executive Officer in March 2013 at which time he was Chief Operating Officer
- Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia

INVESTMENT HIGHLIGHTS



Australian-founded
**clinical stage
drug developer.**



Backed **by
specialist healthcare
investors** –
47% institutional.



**Multiple shots on
goal** from additional
Phase 2, Phase 1 and
preclinical assets.



Funded into 2027 with
**near term data to drive
value** over the next
12-18 months.
(Proforma Sep 25; \$14.4m)



Focus on first-in-class
and best-in-class drugs
backed by **in house long-life
patent portfolio.**



Experienced team
with **proven track
record** in licensing
deals – \$100m raised.



Three Phase 2 studies in
blood cancer indications
with addressable market
value >\$4.5 bn.



\$11.5m in non-dilutive
grant funding
awarded in last 3 years.

POSITIVE 52 WEEK TOP LINE DATA FROM PHASE 2 BLOOD CANCER TRIAL
Safety and tolerability of amsulostat, together with the increasing size and durability of clinical benefit seen beyond 24 weeks, compares very favourably with other drugs in development

SHAREHOLDERS & CASH

Financial Information (ASX: SNT)

Share price – 02 February 2026	\$0.032
Market cap	A\$52.2m
Cash balance – 31 December 2025	A\$12.3m
Enterprise value	A\$39.9m

Institutional Ownership

30 Sept 25

D&A Income Limited	18%
Platinum Investment Management Limited	10%
Total Institutional Ownership	> 43.4%

Research Coverage

Canaccord Genuity	Euroz Hartleys
Bell Potter	Evolution Capital

Share Price & Volume – YTD



* 21 May 2025 recorded volume was 303,525,200 due to internal crossing of stock by substantial holder (maintains same beneficial owner)






** 19 June 2025 recorded volume was 127,701,110 due to block trade of shares between institutions

*** 11 August 2025 recorded volume was 119,820,710 following announcement of FDA guidance for amsulostat

Investment highlights as we head into 2026

- **Lead asset amsulostat continues to build momentum**
 - Amsulostat clinical and preclinical data presented at American Society of Hematology (ASH) Annual Meeting in Orlando
 - Second myelodysplastic syndrome (MDS) study initiated with launch of amsulostat Phase 2 Australian MESSAGE trial in transfusion-dependent low and intermediate risk patients
 - Positive European Medicines Agency opinion received for Orphan Drug Designation of amsulostat in myelofibrosis
 - Pancreatic cancer Phase 1/2 clinical trial of amsulostat in collaboration with the Garvan, funded by MRFF, announced post quarter end
- **Pipeline assets progress**
 - SNT-4728 Phase 2 iRBD trial fully recruited with data expected in Q2 2026, triggering payment of \$1.8 million expected in Q1 2026
 - Progression of topical anti-fibrotic SNT-9465 into hypertrophic scar study following successful completion of Phase 1a study
- **Proforma cash balance at 31 December of \$12.3 million**

THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE

TARGET	DRUG	INDICATION	PARTNERS	PHASE 1		PHASE 2	NEWS FLOW	
				HEALTHY PARTICIPANTS	PATIENTS		H1 2026	H2 2026
Pan-LOX	Amsulostat (SNT-5505)	Myelofibrosis		→			FDA approved development plan and partner engagement	
		High Risk MDS AZALOX trial		→			Interim safety and efficacy data	Phase 2 initiation
		Low / Int Risk MDS MESSAGE trial		→				Interim safety and efficacy data
		Pancreatic cancer		→				Trial initiation
Topical Pan-LOX	SNT-9465	Hypertrophic scarring		→			Recruit hypertrophic scar Phase 1b trial	Top Line safety and efficacy data
	SNT-6302	Keloid scarring		→			Interim safety and efficacy data	
Dual SSAO & MAO-B	SNT-4728	IRBD / Parkinson's Disease	In partnership with 	→			Phase 2 Top Line data	

The image features a large, stylized graphic of the letters 'Q & A' in a white, sans-serif font. The letters are centered within a dark blue, rounded rectangular frame. The background of the entire image is a gradient that transitions from a deep purple on the left to a bright cyan on the right. The 'Q' and 'A' are partially enclosed by the frame, with the 'Q' on the left and the 'A' on the right, and the ampersand in the middle. The overall design is clean and modern.

Q & A



Syntara Limited ABN 75 082 811 630

www.syntaraTX.com.au



Gary Phillips

Chief Executive Officer

gary.phillips@syntaraTX.com.au